<DOC>
	<DOC>NCT02379663</DOC>
	<brief_summary>This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.</brief_summary>
	<brief_title>Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Osteoarthritis, Hip</mesh_term>
	<mesh_term>Femoral Neck Fractures</mesh_term>
	<mesh_term>Femur Head Necrosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male or female without childbearing potential aged ≥20 years who were scheduled for elective primary THA recent history of active bleeding or VTE known genetic disorder associated with bleeding tendency or any condition related with an increased risk of bleeding persistent blood pressure of ≥160mmHg systolic and/or ≥100 mmHg diastolic at baseline myocardial infarction or cerebrovascular accident within three months of the scheduled surgery major surgery in the prior three months renal insufficiency with a creatinine clearance &lt;60mL/min , hepatic failure combined with coagulopathy, or thrombocytopenia (platelets &lt; 100,000/mm³), or planned indwelling epidural catheter for &gt; 6 hours after the end of surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>